Yoshihisa Matsukawa

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study

Robert J. Motzer, Camillo Porta, Masatoshi Eto et al. · Journal of Clinical Oncology · 2024 · 158 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Regenerative treatment of male stress urinary incontinence by periurethral injection of autologous adipose‐derived regenerative cells: 1‐year outcomes in 11 patients

Momokazu Gotoh, Tokunori Yamamoto, Masashi Kato et al. · International Journal of Urology · 2013 · 102 citations · Full text

Medicine, Surgery, Urology +17

Psychometric validation of the Japanese version of the International Consultation on Incontinence Questionnaire‐Short Form

Momokazu Gotoh, Yukio Homma, Yasuhito Funahashi et al. · International Journal of Urology · 2009 · 90 citations

Medicine, Urology, Health Assessment +16